NCT04346381View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

PHASE2CompletedINTERVENTIONAL

Enrollment

233

Participants

Timeline

Start Date

June 5, 2020

Primary Completion Date

June 22, 2022

Study Completion Date

June 22, 2022

Conditions

Solid Tumor

Interventions

DRUG

Camrelizumab

Intravenous (IV) camrelizumab on Day 1 of each cycle

DRUG

Famitinib

famitinib po qd

Trial Locations (1)

Unknown

Fudan University Zhongshan Hospital, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04346381 - Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor | Biotech Hunter | Biotech Hunter